Literature DB >> 23611

Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

R M Kobayashi.   

Abstract

Orofacial or tardive dyskinesias are involuntary repetitive movements of the mouth and face. In most cases, they occur in older psychotic patients who are in institutions and in whom long-term treatment with antipsychotic drugs of the phenothiazine and butyrophenone groups is being carried out. These dyskinesias are frequent in occurrence and characteristically are irreversible. Several biochemical mechanisms have been proposed as causes, including hypersensitivity or partially deneverated brain dopamine receptors and low affinity of the offending drugs for brain muscarinic cholinergic receptors. Clinical therapy has been attempted primarily with drugs that antagonize dopamine receptors or deplete brain dopamine. The benefits of drug treatment have been variable and lack of consistent improvement has been discouraging. Early recognition of dyskinesia should be attempted, and the dose reduced or the drug omitted at the first sign.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 23611      PMCID: PMC1237309     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  81 in total

1.  Tetrabenazine for extra-pyramidal movement disorders.

Authors:  W A MacCallum
Journal:  Br Med J       Date:  1970-03-21

2.  Neuropathological investigation of 28 brains from patients with dyskinesia.

Authors:  E Christensen; J E Moller; A Faurbye
Journal:  Acta Psychiatr Scand       Date:  1970       Impact factor: 6.392

3.  Pyridoxine for levodopa-induced dystonia.

Authors:  H D Jameson
Journal:  JAMA       Date:  1970-03-09       Impact factor: 56.272

4.  Oral dyskinesias--occurrence and treatment.

Authors:  J B Dynes
Journal:  Dis Nerv Syst       Date:  1970-12

5.  Amantadine for dyskinesia tarda.

Authors:  S Vale; M A Espejel
Journal:  N Engl J Med       Date:  1971-03-25       Impact factor: 91.245

6.  Persistence of neurological symptoms due to neuroleptic drugs.

Authors:  G E Crane
Journal:  Am J Psychiatry       Date:  1971-04       Impact factor: 18.112

7.  Amantadine hydrochloride treatment of tardive dyskinesia.

Authors:  B L Decker; J M Davis; D S Jonowsky; M K el-Yousef; H J Sekerke
Journal:  N Engl J Med       Date:  1971-10-07       Impact factor: 91.245

8.  A study of facial dyskinesia in a mental hospital population.

Authors:  S Brandon; H A McClelland; C Protheroe
Journal:  Br J Psychiatry       Date:  1971-02       Impact factor: 9.319

9.  Extrapyramidal disorders after prolonged phenothiazine therapy.

Authors:  P F Kennedy; H I Hershon; R J McGuire
Journal:  Br J Psychiatry       Date:  1971-05       Impact factor: 9.319

10.  Failure of pyridoxine to reduce drug-induced dyskinesias.

Authors:  G E Crane; I S Turek; A A Kurland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

View more
  1 in total

1.  Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism.

Authors:  Marzyeh Kamyar; Bibi Marjan Razavi; Faezeh Vahdati Hasani; Soghra Mehri; Amir Foroutanfar; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.